Anticancer Agents - Novel Spirohexenolides
- Detailed Technology Description
- UC San Diego inventors have received a patent on a new chemical compound, isolated from a natural product that can inhibit progression through the cell cycle. The new structure's use as an anti-cancer agent is in the early stage of preclinical studies. This technology relates to novel spirohexenolides, biosynthetic methods for producing these spirohexenolides. and methods of treating cancer using the novel spirohexenolides. This patented technology is available for commercial development within the United States (USA). Detailed description is available in the hyperlinked US Patent 8,653,283.
- Application No.
- 8653283
- Others
-
Related Materials
Kang MinJin , Brian D. Jones, Alexander L. Mandel, Justin C. Hammons, Antonio G. DiPasquale, Arnold L. Rheingold, James J. La Clair and Michael D. Burkart (2009) Isolation, Structure Elucidation, and Antitumor Activity of Spirohexenolides A and B J. Org. Chem, 2009, 74, 9054-9062.
Yu WL, Jones BD, Kang M, Hammons JC, La Clair JJ, Burkart MD. Spirohexenolide A targets human macrophage migration inhibitory factor (hMIF). J Nat Prod. 2013 May 24;76(5):817-23.Additional Technologies by these Inventors
- Analogs of the Cytotoxic Natural Product Mycolactone
- Synthetic Anticancer Polyketide Compounds
- Reversible Chemoenzymatic Protein Labeling
Tech ID/UC Case
19781/2008-188-0
Related Cases
2008-188-0
- *Abstract
-
None
- *IP Issue Date
- Feb 18, 2014
- *Principal Investigator
-
Name: Michael Burkart
Department:
Name: Brian Jones
Department:
Name: MinJin Kang
Department:
Name: James La Clair
Department:
Name: Alexander Mandel
Department:
Name: Justin Hammons
Department:
Name: Wei-Luen Yu
Department:
- Country/Region
- USA
